trending Market Intelligence /marketintelligence/en/news-insights/trending/dzeeihk4cekhg4g4-jdlfa2 content esgSubNav
In This List

Motif Bio's antibiotic medicine granted priority review by US FDA

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Motif Bio's antibiotic medicine granted priority review by US FDA

New York-based Motif Bio PLC said the U.S. Food and Drug Administration has accepted and granted priority review to its new drug application seeking approval for iclaprim, an antibiotic for treating bacterial skin infections.

The regulator plans to make a decision on the application by Feb. 13, 2019.

The antibiotic is meant to treat acute bacterial skin and skin structure infections, an infection of the skin and associated soft tissues.

Motif's application is supported by the data from two late-stage clinical trials which showed the drug worked as well as the current standard of care vancomycin.

The drug may also be eligible for 10 years of market exclusivity in the U.S.